Canada markets open in 7 hours 35 minutes
  • S&P/TSX

    20,244.29
    +89.75 (+0.45%)
     
  • S&P 500

    4,354.19
    -3.54 (-0.08%)
     
  • DOW

    33,919.84
    -50.63 (-0.15%)
     
  • CAD/USD

    0.7818
    +0.0013 (+0.17%)
     
  • CRUDE OIL

    70.51
    -0.05 (-0.07%)
     
  • BTC-CAD

    53,698.77
    -974.32 (-1.78%)
     
  • CMC Crypto 200

    1,040.43
    -23.42 (-2.20%)
     
  • GOLD FUTURES

    1,779.10
    +0.90 (+0.05%)
     
  • RUSSELL 2000

    2,186.18
    +3.98 (+0.18%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,059.75
    +35.75 (+0.24%)
     
  • VOLATILITY

    24.36
    -1.35 (-5.25%)
     
  • FTSE

    6,980.98
    +77.07 (+1.12%)
     
  • NIKKEI 225

    29,681.39
    -158.32 (-0.53%)
     
  • CAD/EUR

    0.6666
    +0.0015 (+0.23%)
     

UPDATE 1-EU okays capacity increase at Moderna's U.S. sites

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details)

July 30 (Reuters) - The European drugs regulator on Friday approved a ramp-up in production of active substances used to make COVID-19 shots at Moderna's sites in the United States.

The European Medicines Agency (EMA) estimates the European market could get 40 million doses from Moderna's two approved U.S. facilities in the third quarter.

The agency said the approval reaffirms that the facilities - ModernaTX and Lonza Biologics - will help Moderna increase production capacity at the sites and will have a "significant" impact on the supply of the vaccine, known as Spikevax, in the EU.

EMA's human medicines committee has authorised a total of four manufacturing sites, two in the U.S. and two in Switzerland, for the production of active substances for the Moderna vaccine. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Shailesh Kuber)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting